Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

brentuximab

- PMLiVE

Beyond caring: learning from the unsung advocates in cancer care

Macmillan Cancer Support estimates that there are currently around 1.5 million carers caring for someone who has cancer in the UK. Broadly, carers in and outside cancer contribute around £132...

- PMLiVE

Let’s change the conversation about cancer

The changing identity of cancer

- PMLiVE

Pfizer’s leukaemia drug Mylotarg backed for use in EU

The CHMP’s positive opinion could see the drug return to market after almost eight years

- PMLiVE

Amgen and Allergan win first EU approval for Avastin biosimilar

Mvasi, their version of Roche's blockbuster, is licensed for six types of cancers

Roche and GE Healthcare plan ‘industry first’ digital platform

Co-developed clinical decision support software will begin with cancer and critical care

- PMLiVE

Seattle Genetics’ Adcetris earns FDA priority review status

The win follows a breakthrough designation from the US regulator last year

- PMLiVE

Loxo’s cancer drug pair attracts $1.5bn deal with Bayer

The German pharma group will gain full rights to the drugs outside the US

EU flag

Europe’s cancer drug regulation is ‘broken’, claims study

Suggests EMA oncology approvals could lead to wasted funds and patient harm

Merck to co-lead new oncology big data alliance

Will work with Project Data Sphere to improve cancer care

- PMLiVE

NICE reverses stance on Takeda’s Adcetris

But firm criticises final draft guidance's new restrictions on the non-Hodgkin’s lymphoma drug

- PMLiVE

BMS and Clovis join forces in PARP combo race

Duo will combine Opdivo and Rubraca in phase II and III trials to treat a variety of tumours

- PMLiVE

BMS and Clovis join forces in PARP combo race

Duo will combine Opdivo and Rubraca in phase II and III trials to treat a variety of tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links